Oculis Holding AG OCS 深 滬
已收盤 02-06 16:00:00 美东时间
28.48
+0.990
+3.60%
華盛通- 最 高28.66
- 今 開27.61
- 成交量 27.61万股
- 最 低 27.5101
- 昨 收 27.49
- 總市值 16.46亿
- 52周最高 29.3599
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 14.00
- 委 比 -83.97%
- 總股本 5780.69万
- 歷史最高 29.3599
- 量 比 0.90
- 振 幅 4.18%
- 歷史最低 6.26
- 每 手 1
- 風險率 2.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oculis Holding shares are trading higher after the FDa granted the company's neuroprotective candidate Privosegtor breakthrough therapy designation.
Oculis Holding shares are trading higher after the FDa granted the company's ne...
01-06 22:15
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
JP Morgan Initiates Coverage On Oculis Holding with Overweight Rating, Announces Price Target of $38
JP Morgan analyst Tessa Romero initiates coverage on Oculis Holding (NASDAQ:OCS) with a Overweight rating and announces Price Target of $38.
2025-12-19 20:53
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
LifeSci Capital Initiates Coverage On Oculis Holding with Outperform Rating, Announces Price Target of $55
LifeSci Capital initiates coverage on Oculis Holding (NASDAQ:OCS) with a Outperform rating and announces Price Target of $55.
2025-12-03 21:55
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
Needham Reiterates Buy on Oculis Holding, Maintains $36 Price Target
Needham analyst Serge Belanger reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $36 price target.
2025-11-11 19:04
Oculis Holding Q3 EPS $(0.32) Beats $(0.50) Estimate, Sales $243.000K Miss $250.000K Estimate
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.50) by 36 percent. This is a 41.82 percent increase over losses of $(0.55) per share from the
2025-11-11 05:45
Oculis Raises $110M Through Oversubscribed Offering To Advance Privosegtor Clinical Development And Strengthen Ophthalmology Pipeline
Oculis intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in acute optic neuritis (AON) and non-arteritic anterior
2025-10-30 16:33
